- Home
- UAN vs AVBP Comparison
UAN vs AVBP Comparison
Compare UAN & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- AVBP
- Stock Information
- Founded
- UAN 2007
- AVBP 2021
- Country
- UAN United States
- AVBP United States
- Employees
- UAN N/A
- AVBP N/A
- Industry
- UAN Agricultural Chemicals
- AVBP
- Sector
- UAN Industrials
- AVBP
- Exchange
- UAN Nasdaq
- AVBP NYSE
- Market Cap
- UAN 773.6M
- AVBP 705.8M
- IPO Year
- UAN 2011
- AVBP 2024
- Fundamental
- Price
- UAN $82.68
- AVBP $22.00
- Analyst Decision
- UAN
- AVBP Strong Buy
- Analyst Count
- UAN 0
- AVBP 7
- Target Price
- UAN N/A
- AVBP $39.29
- AVG Volume (30 Days)
- UAN 30.4K
- AVBP 251.3K
- Earning Date
- UAN 07-28-2025
- AVBP 05-12-2025
- Dividend Yield
- UAN 8.58%
- AVBP N/A
- EPS Growth
- UAN N/A
- AVBP N/A
- EPS
- UAN 7.13
- AVBP N/A
- Revenue
- UAN $540,525,000.00
- AVBP N/A
- Revenue This Year
- UAN N/A
- AVBP $63.13
- Revenue Next Year
- UAN N/A
- AVBP N/A
- P/E Ratio
- UAN $11.60
- AVBP N/A
- Revenue Growth
- UAN N/A
- AVBP N/A
- 52 Week Low
- UAN $62.94
- AVBP $15.47
- 52 Week High
- UAN $84.96
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- UAN 60.16
- AVBP 63.80
- Support Level
- UAN $81.26
- AVBP $19.80
- Resistance Level
- UAN $83.99
- AVBP $20.86
- Average True Range (ATR)
- UAN 1.97
- AVBP 1.11
- MACD
- UAN -0.23
- AVBP 0.18
- Stochastic Oscillator
- UAN 55.17
- AVBP 89.26
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.